Study S000223

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection, for Subcutaneous Use in Combination With Semaglutide in Participants With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT06972992
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: COMPLETED
Enrollment: 28
Start: 2025-04-18
Primary completion: 2025-09-22
Lead sponsor: Ascletis Pharma (China) Co., Limited
Conditions: Chronic Weight Management
Interventions: DRUG:ASC47 +Semaglutide; DRUG:Placebo+Semaglutide
Results posted: FALSE

Registered primary outcomes

Adverse events [up to 71 days]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.